CN103596929B - 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮 - Google Patents
作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮 Download PDFInfo
- Publication number
- CN103596929B CN103596929B CN201180067948.3A CN201180067948A CN103596929B CN 103596929 B CN103596929 B CN 103596929B CN 201180067948 A CN201180067948 A CN 201180067948A CN 103596929 B CN103596929 B CN 103596929B
- Authority
- CN
- China
- Prior art keywords
- compound
- hours
- alkyl
- room temperature
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC1(CCC(C2(C)C)=*)C2=CCC1OCOC Chemical compound CC1(CCC(C2(C)C)=*)C2=CCC1OCOC 0.000 description 19
- KTLFWCKMRHNTLE-UHFFFAOYSA-N CC(C)(C1C(C)(CC2C#N)c3n[n](C)c(C(O)=O)c3CC1)C2=O Chemical compound CC(C)(C1C(C)(CC2C#N)c3n[n](C)c(C(O)=O)c3CC1)C2=O KTLFWCKMRHNTLE-UHFFFAOYSA-N 0.000 description 1
- HRVSMHUORGQWOD-FXWZCDFBSA-N CC(C)([C@H]1C(C)(C/C2=C/O)c3n[n](C)c(C(c4ccccc4)=O)c3CC1)C2=O Chemical compound CC(C)([C@H]1C(C)(C/C2=C/O)c3n[n](C)c(C(c4ccccc4)=O)c3CC1)C2=O HRVSMHUORGQWOD-FXWZCDFBSA-N 0.000 description 1
- SUQGETDCZJIKAY-NVHKAFQKSA-N CC(C)([C@H]1C(C)(C=C2C#N)c3n[n](C)c(C(c4ccccc4)=O)c3CC1)C2=O Chemical compound CC(C)([C@H]1C(C)(C=C2C#N)c3n[n](C)c(C(c4ccccc4)=O)c3CC1)C2=O SUQGETDCZJIKAY-NVHKAFQKSA-N 0.000 description 1
- RYRGHCOJOXPSDZ-XNUZUHMRSA-N CC(C)([C@H]1C(C)(CC2)c3n[n](C)c(C(c4ccccc4)=O)c3CC1)C21OCCO1 Chemical compound CC(C)([C@H]1C(C)(CC2)c3n[n](C)c(C(c4ccccc4)=O)c3CC1)C21OCCO1 RYRGHCOJOXPSDZ-XNUZUHMRSA-N 0.000 description 1
- ZDQNHLFVYWDAKN-HSQRQWGBSA-N CC(C)([C@H]1C(C)(CC2)c3n[n](C)c(N)c3CC1)C21[U]CCO1 Chemical compound CC(C)([C@H]1C(C)(CC2)c3n[n](C)c(N)c3CC1)C21[U]CCO1 ZDQNHLFVYWDAKN-HSQRQWGBSA-N 0.000 description 1
- IDIMTBNUTKSCAF-WBWVDOBWSA-N CC(C)([C@H]1C(C)(CC2C#N)c3n[n](C)c(C(c4ccccc4)=O)c3CC1)C2=O Chemical compound CC(C)([C@H]1C(C)(CC2C#N)c3n[n](C)c(C(c4ccccc4)=O)c3CC1)C2=O IDIMTBNUTKSCAF-WBWVDOBWSA-N 0.000 description 1
- XPXBCWZMTIBGPI-ZBEGNZNMSA-N CC(C)([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(Br)c3CC1)C2=O Chemical compound CC(C)([C@H]1[C@](C)(C=C2C#N)c3n[n](C)c(Br)c3CC1)C2=O XPXBCWZMTIBGPI-ZBEGNZNMSA-N 0.000 description 1
- NNJGRVLXWWFDSL-UHFFFAOYSA-N CC1(CCC(C2(C)C)=O)c3n[n](C)cc3CC12N Chemical compound CC1(CCC(C2(C)C)=O)c3n[n](C)cc3CC12N NNJGRVLXWWFDSL-UHFFFAOYSA-N 0.000 description 1
- HMQAJUYTFRUSSF-MBIQTGHCSA-N CC12c3n[n](C)c(C#N)c3CC[C@H]1C(C)(C)OCCOCC2 Chemical compound CC12c3n[n](C)c(C#N)c3CC[C@H]1C(C)(C)OCCOCC2 HMQAJUYTFRUSSF-MBIQTGHCSA-N 0.000 description 1
- IGKLGUNWLMNMTQ-QGZVFWFLSA-N CCCCC(C(C)(C)[C@H]1Cc2n[n](C)c(C(c3ccccc3)=O)c2CC1)=O Chemical compound CCCCC(C(C)(C)[C@H]1Cc2n[n](C)c(C(c3ccccc3)=O)c2CC1)=O IGKLGUNWLMNMTQ-QGZVFWFLSA-N 0.000 description 1
- MJRJOBOEUCPRRX-UHFFFAOYSA-N CCCc1c[n](NC)nc1 Chemical compound CCCc1c[n](NC)nc1 MJRJOBOEUCPRRX-UHFFFAOYSA-N 0.000 description 1
- KWLVXIPZYGAABO-KURKYZTESA-N C[C@@](C1)([C@]11[C@](C)(CC2)c3n[n](C)c(-c4n[n](C)nn4)c3CC1)C21OCCO1 Chemical compound C[C@@](C1)([C@]11[C@](C)(CC2)c3n[n](C)c(-c4n[n](C)nn4)c3CC1)C21OCCO1 KWLVXIPZYGAABO-KURKYZTESA-N 0.000 description 1
- YYJKNOQRSRRGJA-RYUDHWBXSA-N C[C@@](CC1)([C@H](CC2)OCNC)C2=CC1=O Chemical compound C[C@@](CC1)([C@H](CC2)OCNC)C2=CC1=O YYJKNOQRSRRGJA-RYUDHWBXSA-N 0.000 description 1
- BMQFRTMNHUGXBR-CABCVRRESA-N C[C@@]1(C=C(C(C2(C)C)=O)C#N)c3n[n](C)cc3C[C@@]12N Chemical compound C[C@@]1(C=C(C(C2(C)C)=O)C#N)c3n[n](C)cc3C[C@@]12N BMQFRTMNHUGXBR-CABCVRRESA-N 0.000 description 1
- UWLYXTIFPAPOPA-PGZQCDFOSA-N C[C@@]1(CCC2(C3(C)C)[U]CCO2)c2n[n](C)cc2CC13N Chemical compound C[C@@]1(CCC2(C3(C)C)[U]CCO2)c2n[n](C)cc2CC13N UWLYXTIFPAPOPA-PGZQCDFOSA-N 0.000 description 1
- PCTYVBYWTOKBRB-MXPOGPBASA-N C[C@](CC1)([C@H](C/C2=C/O)C(C)(C)C11OCCO1)C2=[U] Chemical compound C[C@](CC1)([C@H](C/C2=C/O)C(C)(C)C11OCCO1)C2=[U] PCTYVBYWTOKBRB-MXPOGPBASA-N 0.000 description 1
- VPROZODPFLFWFM-AIEFZORHSA-N C[C@](CC1)([C@H](CC2)C(C)(C)C1=[U])C2OCOC Chemical compound C[C@](CC1)([C@H](CC2)C(C)(C)C1=[U])C2OCOC VPROZODPFLFWFM-AIEFZORHSA-N 0.000 description 1
- VFBKJZFQVABFEO-PZORYLMUSA-N C[C@](CCC1(C2(C)C)OCCO1)(C2(CC1)N)C1=O Chemical compound C[C@](CCC1(C2(C)C)OCCO1)(C2(CC1)N)C1=O VFBKJZFQVABFEO-PZORYLMUSA-N 0.000 description 1
- QPUYECUOLPXSFR-UHFFFAOYSA-N Cc1cccc2c1cccc2 Chemical compound Cc1cccc2c1cccc2 QPUYECUOLPXSFR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061424601P | 2010-12-17 | 2010-12-17 | |
| US61/424,601 | 2010-12-17 | ||
| PCT/US2011/065897 WO2012083306A2 (en) | 2010-12-17 | 2011-12-19 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103596929A CN103596929A (zh) | 2014-02-19 |
| CN103596929B true CN103596929B (zh) | 2016-10-19 |
Family
ID=45470714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180067948.3A Active CN103596929B (zh) | 2010-12-17 | 2011-12-19 | 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮 |
Country Status (32)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE043175T2 (hu) | 2008-01-11 | 2019-08-28 | Reata Pharmaceuticals Inc | Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében |
| MX339476B (es) | 2008-04-18 | 2016-05-27 | Reata Pharmaceuticals Inc | Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso. |
| ES2703274T3 (es) | 2008-04-18 | 2019-03-07 | Reata Pharmaceuticals Inc | Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17 |
| PH12013501254A1 (en) | 2010-12-17 | 2016-07-29 | Novartis Ag | Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
| HRP20171859T1 (hr) | 2010-12-17 | 2018-01-26 | Reata Pharmaceuticals, Inc. | Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale |
| DK3444261T3 (da) | 2012-04-27 | 2021-03-08 | Reata Pharmaceuticals Inc | 2,2-difluorpropionamidderivat af bardoxolonmethyl, farmaceutiske sammensætninger og polymorfer deraf til anvendelse ved behandling af visse lidelser |
| US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| PL2892912T3 (pl) | 2012-09-10 | 2019-10-31 | Reata Pharmaceuticals Inc | C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania |
| TWI649330B (zh) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法 |
| MX372772B (es) * | 2014-01-24 | 2020-06-29 | Reata Pharmaceuticals Inc | Enonas piridazolilo y pirimidinilo tricíclicas sustituidas con arilo y arilalquilo como moduladores de la inflamación antioxidantes. |
| US11059792B2 (en) | 2015-02-12 | 2021-07-13 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant inflammation modulators |
| AU2017356955B2 (en) | 2016-11-08 | 2023-11-09 | Reata Pharmaceuticals Holdings, LLC | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof |
| TWI831738B (zh) * | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| US11286226B2 (en) | 2017-09-21 | 2022-03-29 | Northwestern University | Polycyclic carbogenic molecules and uses thereof as anti-cancer agents |
| WO2019104030A1 (en) * | 2017-11-21 | 2019-05-31 | Biogen Ma Inc. | Tetrahydronaphthalene derivatives useful as nrf2 activators |
| CN112654610B (zh) * | 2018-06-15 | 2024-12-24 | 里亚塔医药公司 | 用于抑制IL-17和RORγ的吡唑和咪唑化合物 |
| EP3810141A1 (en) | 2018-06-20 | 2021-04-28 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| CN114945561A (zh) | 2020-01-13 | 2022-08-26 | 阿普塔生物治疗公司 | 新吡唑衍生物 |
| US20250025465A1 (en) * | 2021-11-17 | 2025-01-23 | Northwestern University | Wt-idh1 inhibition using a covalent and brain-penetrant small molecular inhibitor for ferroptosis induction in high-grade glioma |
| CN121358860A (zh) * | 2023-06-16 | 2026-01-16 | 南京科捷基因技术有限公司 | 肿瘤特异性表达盒及其用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN85101752A (zh) * | 1983-10-03 | 1987-01-31 | 美国辉瑞有限公司 | 2-胺基-5-羟基-4-甲基嘧啶衍生物的制备方法 |
| CN1162918A (zh) * | 1994-09-09 | 1997-10-22 | 小山省三 | 分子表达功能抑制剂 |
| CN1491225A (zh) * | 2000-12-28 | 2004-04-21 | СҰҩƷ��ҵ��ʽ���� | 三杂环化合物和包括其作为活性组分的药物 |
| WO2009146216A2 (en) * | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| WO2009146218A2 (en) * | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2875201A (en) | 1957-08-28 | 1959-02-24 | Searle & Co | Dehydrotigogenone intermediates |
| US3071577A (en) * | 1959-08-13 | 1963-01-01 | Syntex Corp | Pyrimidinyl androstanes |
| US3994935A (en) | 1975-11-24 | 1976-11-30 | E. R. Squibb & Sons, Inc. | Steroidal 16β-alkyl[16α,17-b]naphthalenes |
| US4395423A (en) | 1978-10-10 | 1983-07-26 | Sterling Drug Inc. | Polycyclic cyanoketones |
| NZ191586A (en) | 1978-10-10 | 1981-10-19 | Sterling Drug Inc | Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions |
| US5064823A (en) | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
| DE4014171A1 (de) | 1990-05-03 | 1991-11-07 | Basf Ag | Cyanochinolinverbindungen |
| JPH08208479A (ja) * | 1994-04-29 | 1996-08-13 | Takeda Chem Ind Ltd | クラビンアルカロイド誘導体を含有する鎮痛剤 |
| WO1995029912A1 (en) | 1994-04-29 | 1995-11-09 | Takeda Chemical Industries, Ltd. | Ergoline derivatives as analgesics |
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US6369101B1 (en) | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
| US6365768B1 (en) | 1999-05-14 | 2002-04-02 | Nereus Pharmaceuticals, Inc. | Interleukin-1 and tumor necrosis factors-α modulators, syntheses of said modulators and methods of using modulators |
| US6649654B1 (en) | 1999-11-23 | 2003-11-18 | The Regents Of The University Of California | Methods for identifying and using IKK inhibitors |
| US6890946B2 (en) | 1999-12-23 | 2005-05-10 | Indiana University Research And Technology Corporation | Use of parthenolide to inhibit cancer |
| US7087599B2 (en) | 2000-02-14 | 2006-08-08 | Merck & Co., Inc. | Estrogen receptor modulators |
| JP2001240573A (ja) | 2000-03-01 | 2001-09-04 | Meiji Seika Kaisha Ltd | トリテルペン誘導体及び肝疾患治療剤 |
| WO2002003996A1 (en) | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
| JP2004509972A (ja) | 2000-09-29 | 2004-04-02 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 酵母に対する殺真菌活性を有するトリテルペン |
| US6951847B2 (en) | 2000-09-29 | 2005-10-04 | Regents Of The University Of Minnesota | Methods of treating fungal infections using lupeol |
| AU2001294959A1 (en) | 2000-09-29 | 2002-04-08 | Robert M. Carlson | Triterpenes having antibacterial activity |
| US6878751B1 (en) | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
| US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| EP1395255A4 (en) | 2000-11-28 | 2007-09-12 | Univ Texas | CDDO COMPOUNDS AND COMBINATION THERAPIES THEREOF |
| AU2002308701A1 (en) | 2001-05-14 | 2002-11-25 | University Of Maryland, Baltimore | Novel alanine transaminase enzyme and methods of use |
| CA2456150A1 (en) | 2001-08-13 | 2003-02-27 | Merck & Co., Inc. | Selective estrogen receptor modulators |
| WO2003024935A2 (en) | 2001-09-19 | 2003-03-27 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
| US6991814B2 (en) | 2001-12-13 | 2006-01-31 | Council Of Scientific And Industrial Research | Herbal medicaments for the treatment of neurocerebrovascular disorders |
| US7176237B2 (en) | 2002-01-15 | 2007-02-13 | The Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
| MXPA04006953A (es) | 2002-01-18 | 2005-06-20 | Univ Minnesota | Sales cuaternarias de triperpeno como surfactantes biologicamente activos. |
| JP2005534286A (ja) | 2002-03-21 | 2005-11-17 | サネシス ファーマシューティカルズ， インコーポレイテッド | キナーゼインヒビターの同定 |
| AU2003303128A1 (en) | 2002-05-13 | 2004-08-13 | Trustees Of Dartmouth College | Inhibitors and methods of use thereof |
| WO2004089357A2 (en) | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
| CN1845750B (zh) | 2003-09-02 | 2014-05-07 | 尤尼根公司 | 用于预防及治疗认知衰退和年龄相关的记忆障碍的无取代b环类黄酮和黄烷混合物的组合物 |
| WO2005042002A2 (en) | 2003-10-30 | 2005-05-12 | Entelos, Inc. | Treatment of rhematoid arthritis with flip antagonists |
| US8288439B2 (en) | 2003-11-04 | 2012-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the inhibition of HIV-1 replication |
| US20060258752A1 (en) | 2004-02-12 | 2006-11-16 | Vander Jagt David L | Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors |
| JP2005314381A (ja) | 2004-03-30 | 2005-11-10 | Anges Mg Inc | 増殖性腎疾患の予防・治療・改善剤 |
| CA2579231C (en) | 2004-09-07 | 2018-07-10 | Pacific Arrow Limited | Anti-tumor compounds with angeloyl groups |
| WO2006089406A1 (en) * | 2005-02-22 | 2006-08-31 | Gemin X Biotechnologies Inc. | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents |
| US7902196B2 (en) | 2005-03-17 | 2011-03-08 | President And Fellows Of Harvard College | Synthesis of avrainvillamide, strephacidin B, and analogues thereof |
| WO2007005879A2 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| DE102005041613A1 (de) | 2005-09-01 | 2007-03-08 | Ergonex Pharma Gmbh | Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom |
| US20070232577A1 (en) | 2006-03-23 | 2007-10-04 | Advanced Life Sciences, Inc. | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin |
| WO2007127791A2 (en) | 2006-04-25 | 2007-11-08 | The Administrators Of The Tulane Educational Fund | New pharmacological method for treatment of neuropathic pain |
| EP2032594B1 (en) | 2006-06-27 | 2015-09-23 | Wellington Laboratories Inc. | Glycyrrhetinic acid derivatives |
| WO2008016095A1 (en) | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT |
| JP2008110962A (ja) | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
| US8735411B2 (en) | 2006-10-02 | 2014-05-27 | Abbvie Inc. | Macrocyclic benzofused pyrimidine derivatives |
| US20090203661A1 (en) | 2006-10-12 | 2009-08-13 | Safe Stephen H | Betulinic acid, derivatives and analogs thereof and uses therefor |
| US8299046B2 (en) | 2006-11-17 | 2012-10-30 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
| WO2008064133A1 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| DK2653873T3 (da) | 2007-02-08 | 2022-07-25 | Biogen Ma Inc | Sammensætninger og anvendelser til behandling af multipel sklerose |
| WO2008111497A1 (ja) | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| US20090048205A1 (en) | 2007-08-15 | 2009-02-19 | Colin Meyer | Combination therapy with synthetic triterpenoids and gemcitabine |
| WO2009058849A1 (en) | 2007-10-29 | 2009-05-07 | University Of Rochester | Use of electrophilic compounds for inducing platelet production or maintaining platelet function |
| HUE043175T2 (hu) | 2008-01-11 | 2019-08-28 | Reata Pharmaceuticals Inc | Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében |
| KR101713140B1 (ko) | 2008-04-18 | 2017-03-08 | 리타 파마슈티컬스 잉크. | Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체 |
| CN104250280A (zh) | 2008-04-18 | 2014-12-31 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物 |
| ES2703274T3 (es) | 2008-04-18 | 2019-03-07 | Reata Pharmaceuticals Inc | Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17 |
| WO2009134726A1 (en) | 2008-04-28 | 2009-11-05 | Abbott Laboratories | Substituted pyrimidine derivatives as histamine h4 receptor ligands |
| EP2309860B1 (en) | 2008-07-22 | 2014-01-08 | Trustees of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
| WO2010053817A1 (en) | 2008-11-04 | 2010-05-14 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
| PL3254675T3 (pl) | 2009-02-13 | 2019-09-30 | Reata Pharmaceuticals, Inc. | Kompozycje doustne o opóźnionym uwalnianiu, zawierające amorficzny cddo-me |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| SMT202000086T1 (it) | 2010-04-12 | 2020-03-13 | Reata Pharmaceuticals Inc | Bardoxolone metile per il trattamento dell'obesità |
| CN102079772A (zh) | 2010-12-09 | 2011-06-01 | 中国药科大学 | 一类五环三萜-13,28-内酯化合物、其制备方法和用途 |
| HRP20171859T1 (hr) | 2010-12-17 | 2018-01-26 | Reata Pharmaceuticals, Inc. | Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale |
| MX2013006936A (es) | 2010-12-17 | 2013-07-22 | Du Pont | Ambas azociclicas fungicidas. |
| JP6001560B2 (ja) | 2011-01-31 | 2016-10-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｉｖ成熟阻害活性を有するｃ−１７およびｃ−３修飾トリテルペノイド |
| CA2829618C (en) | 2011-03-11 | 2019-07-09 | Reata Pharmaceuticals, Inc. | C4-monomethyl triterpenoid derivatives and methods of use thereof |
| DK3444261T3 (da) | 2012-04-27 | 2021-03-08 | Reata Pharmaceuticals Inc | 2,2-difluorpropionamidderivat af bardoxolonmethyl, farmaceutiske sammensætninger og polymorfer deraf til anvendelse ved behandling af visse lidelser |
| US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| PL2892912T3 (pl) | 2012-09-10 | 2019-10-31 | Reata Pharmaceuticals Inc | C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| HRP20171565T1 (hr) | 2012-09-10 | 2017-12-15 | Reata Pharmaceuticals, Inc. | C17-heteroaril derivati oleanolne kiseline i postupci njihove uporabe |
| NZ774222A (en) | 2013-08-23 | 2023-01-27 | Reata Pharmaceuticals Holdings Llc | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
-
2011
- 2011-12-19 HR HRP20171859TT patent/HRP20171859T1/hr unknown
- 2011-12-19 SG SG2013046198A patent/SG191181A1/en unknown
- 2011-12-19 LT LTEP11807826.0T patent/LT2651902T/lt unknown
- 2011-12-19 AR ARP110104761A patent/AR084353A1/es active IP Right Grant
- 2011-12-19 SI SI201131385T patent/SI2651902T1/en unknown
- 2011-12-19 PT PT118078260T patent/PT2651902T/pt unknown
- 2011-12-19 DK DK11807826.0T patent/DK2651902T3/en active
- 2011-12-19 RS RS20180025A patent/RS56795B1/sr unknown
- 2011-12-19 NZ NZ612788A patent/NZ612788A/en unknown
- 2011-12-19 JP JP2013544872A patent/JP5857068B2/ja active Active
- 2011-12-19 WO PCT/US2011/065897 patent/WO2012083306A2/en not_active Ceased
- 2011-12-19 HU HUE11807826A patent/HUE038046T2/hu unknown
- 2011-12-19 CN CN201180067948.3A patent/CN103596929B/zh active Active
- 2011-12-19 SM SM20180069T patent/SMT201800069T1/it unknown
- 2011-12-19 ES ES11807826.0T patent/ES2653717T3/es active Active
- 2011-12-19 KR KR1020137018672A patent/KR102000301B1/ko active Active
- 2011-12-19 EP EP11807826.0A patent/EP2651902B1/en active Active
- 2011-12-19 EA EA201390894A patent/EA025568B1/ru unknown
- 2011-12-19 BR BR112013015241-9A patent/BR112013015241B1/pt active IP Right Grant
- 2011-12-19 NO NO11807826A patent/NO2651902T3/no unknown
- 2011-12-19 AU AU2011343466A patent/AU2011343466B2/en active Active
- 2011-12-19 TW TW100147581A patent/TWI527788B/zh active
- 2011-12-19 US US13/330,378 patent/US8513436B2/en active Active
- 2011-12-19 PL PL11807826T patent/PL2651902T3/pl unknown
- 2011-12-19 MX MX2013006902A patent/MX2013006902A/es unknown
- 2011-12-19 ME MEP-2017-298A patent/ME02973B/me unknown
- 2011-12-19 CA CA2822071A patent/CA2822071C/en active Active
-
2013
- 2013-06-13 IL IL226923A patent/IL226923A/en active IP Right Grant
- 2013-06-17 CL CL2013001754A patent/CL2013001754A1/es unknown
- 2013-07-05 ZA ZA2013/05060A patent/ZA201305060B/en unknown
- 2013-07-11 US US13/939,818 patent/US9174941B2/en active Active
- 2013-07-15 CO CO13167243A patent/CO6910185A2/es active IP Right Grant
-
2015
- 2015-10-08 US US14/877,974 patent/US9884809B2/en active Active
-
2018
- 2018-01-04 US US15/861,758 patent/US20180265455A1/en not_active Abandoned
- 2018-02-05 CY CY20181100134T patent/CY1120032T1/el unknown
-
2019
- 2019-12-03 US US16/701,585 patent/US11192852B2/en active Active
-
2021
- 2021-12-06 US US17/457,808 patent/US11814338B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN85101752A (zh) * | 1983-10-03 | 1987-01-31 | 美国辉瑞有限公司 | 2-胺基-5-羟基-4-甲基嘧啶衍生物的制备方法 |
| CN1162918A (zh) * | 1994-09-09 | 1997-10-22 | 小山省三 | 分子表达功能抑制剂 |
| CN1491225A (zh) * | 2000-12-28 | 2004-04-21 | СҰҩƷ��ҵ��ʽ���� | 三杂环化合物和包括其作为活性组分的药物 |
| WO2009146216A2 (en) * | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| WO2009146218A2 (en) * | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
Non-Patent Citations (2)
| Title |
|---|
| NEW ENONE DERIVATIVES OF OLEANOLIC ACID AND URSOLIC ACID AS INHIBITORS OF NITRIC OXIDE PRODUCTION IN MOUSE MACROPHAGES;Tadashi Honda,等;《Bioorganic & Medicinal Chemistry Letters》;19970708;第7卷(第13期);第1623-1628页 * |
| Versatile Strategy to Access Tricycles Related to Quassinoids and Triterpenes;Pierre-Yves Caron,等;《Organic Letters》;20100107;第12卷(第3期);第510页方案7中化合物27 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103596929A (zh) | 作为抗氧化发炎调节剂的吡唑及嘧啶三环烯酮 | |
| CN104955833B (zh) | 齐墩果酸的c17-烷二基与烯二基衍生物及其使用方法 | |
| JP6129084B2 (ja) | Ｃ４−モノメチルトリテルペノイド誘導体およびその使用方法 | |
| CN107428698A (zh) | 作为抗氧化炎症调节剂的咪唑基三环烯酮 | |
| KR20230147077A (ko) | 합성 우르솔산 유도체 및 이의 사용 방법 | |
| HK1189595B (en) | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | |
| HK1212355B (zh) | 齐墩果酸的c17-烷二基与烯二基衍生物及其使用方法 | |
| HK1189894A (en) | C4-monomethyl triterpenoid derivatives and methods of use thereof | |
| HK1189894B (en) | C4-monomethyl triterpenoid derivatives and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1189595 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1189595 Country of ref document: HK |